| Small cell carcinoma of lung
Tecentriq vs Zepzelca
Side-by-side clinical, coverage, and cost comparison for small cell carcinoma of lung.Deep comparison between: Tecentriq vs Zepzelca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZepzelca has a higher rate of injection site reactions vs Tecentriq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zepzelca but not Tecentriq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tecentriq
Zepzelca
At A Glance
IV infusion
Every 2-4 weeks
PD-L1 antagonist
IV infusion
Every 21 days
Alkylating drug
Indications
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Liver carcinoma
- Melanoma
- Alveolar Soft Part Sarcoma
- Small cell carcinoma of lung
- Small cell lung cancer extensive stage
- Small cell lung cancer metastatic
Dosing
Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.
Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.
Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.
Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.
Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.
Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.
Small cell lung cancer extensive stage 3.2 mg/m2 IV infusion over 60 minutes every 21 days in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs until disease progression or unacceptable toxicity; reduce to 1.6 mg/m2 every 21 days for moderate or severe hepatic impairment.
Small cell lung cancer metastatic 3.2 mg/m2 IV infusion over 60 minutes every 21 days as a single agent until disease progression or unacceptable toxicity; reduce to 1.6 mg/m2 every 21 days for moderate or severe hepatic impairment.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).
Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.
Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.
Most common (>=30%) Decreased lymphocytes, decreased platelets, decreased hemoglobin, decreased neutrophils, nausea, fatigue
Serious Pneumonia, sepsis, cardio-respiratory arrest, myocardial infarction, febrile neutropenia
Postmarketing Extravasation with tissue necrosis requiring debridement, rhabdomyolysis, tumor lysis syndrome
Pharmacology
Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts that disrupt DNA binding proteins and repair pathways, leading to cell cycle perturbation and cell death; it also inhibits monocyte activity and reduces macrophage tumor infiltration in vivo.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tecentriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Zepzelca
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Tecentriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zepzelca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tecentriq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Zepzelca
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tecentriq.
$10
JazzCares Copay Program: ZepzelcaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TecentriqView full Tecentriq profile
ZepzelcaView full Zepzelca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.